How Joenja works
Joenja is designed to correct the underlying immune defect caused by APDS to help normalize the hyperactive PI3Kδ pathway
Jump to section:
How Joenja works
Joenja in action
HOW JOENJA WORKS
Joenja is the first and only precision therapy that corrects the underlying immune defect in patients 4 years and older with APDS
Joenja changes the trajectory of APDS by targeting the underlying immune defect and normalizing the hyperactive PI3Kδ pathway
Only Joenja specifically targets and blocks the PI3Kδ protein, addressing immune dysregulation and deficiency at the earliest stage of the PI3K pathway
Joenja facilitates a balanced PI3Kδ pathway to support proper immune function
JOENJA IN ACTION
Joenja mechanism of action
This video provides a detailed illustration of the mechanism of action for Joenja and shows how only Joenja addresses both immune deficiency AND immune dysregulation to help normalize immune balance.
AKT/PKB, protein kinase B; APDS, activated PI3Kδ syndrome; FOXO, forkhead box O; mTOR, mammalian target of rapamycin; p85α, the regulatory subunit of the PI3Kδ enzyme; p110δ, the catalytic subunit of the PI3Kδ enzyme; PDK1, phosphoinositide-dependent kinase 1; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate.
Efficacy results
(For ages 12+)
→
APDS Assist
→
